| Mrs Leila Keel Nichols, CNM | |
|
2863 Highway 45 Byp, Jackson, TN 38305-3618 | |
| (731) 660-8300 | |
| (731) 660-8301 |
| Full Name | Mrs Leila Keel Nichols |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 16 Years |
| Location | 2863 Highway 45 Byp, Jackson, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104159904 | NPI | - | NPPES |
| 3380640 | Other | TN | MEDICARE GROUP |
| 3380640 | Other | TN | MEDICAID GROUP |
| 1525515 | Medicaid | TN |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jackson Clinic Pa | 2668376872 | 176 |
News Archive
Consumers are now in the era of "on-demand" entertainment, in which they have access to the books, music and movies they want thanks to the internet. Likewise, scientists who use synchrotron light sources are welcoming an era of "on-demand" X-rays, in which they have access to the light beams they want thanks to a technique developed at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
› Verified 9 days ago
| Entity Name | Jackson Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285629386 PECOS PAC ID: 2668376872 Enrollment ID: O20040318000962 |
News Archive
Consumers are now in the era of "on-demand" entertainment, in which they have access to the books, music and movies they want thanks to the internet. Likewise, scientists who use synchrotron light sources are welcoming an era of "on-demand" X-rays, in which they have access to the light beams they want thanks to a technique developed at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
› Verified 9 days ago
| Entity Name | Obhg Tennessee, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285924977 PECOS PAC ID: 1850566514 Enrollment ID: O20111207000456 |
News Archive
Consumers are now in the era of "on-demand" entertainment, in which they have access to the books, music and movies they want thanks to the internet. Likewise, scientists who use synchrotron light sources are welcoming an era of "on-demand" X-rays, in which they have access to the light beams they want thanks to a technique developed at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
› Verified 9 days ago
| Entity Name | Wt University Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023572344 PECOS PAC ID: 3779824719 Enrollment ID: O20190401001719 |
News Archive
Consumers are now in the era of "on-demand" entertainment, in which they have access to the books, music and movies they want thanks to the internet. Likewise, scientists who use synchrotron light sources are welcoming an era of "on-demand" X-rays, in which they have access to the light beams they want thanks to a technique developed at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Leila Keel Nichols, CNM Po Box 400, Jackson, TN 38302-0400 Ph: (731) 422-0213 | Mrs Leila Keel Nichols, CNM 2863 Highway 45 Byp, Jackson, TN 38305-3618 Ph: (731) 660-8300 |
News Archive
Consumers are now in the era of "on-demand" entertainment, in which they have access to the books, music and movies they want thanks to the internet. Likewise, scientists who use synchrotron light sources are welcoming an era of "on-demand" X-rays, in which they have access to the light beams they want thanks to a technique developed at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).
GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.
UT Arlington and Texas Health Arlington Memorial Hospital are investigating whether bone grown from the body's own stem cells can replace traditional types of bone grafting.
Micromet, Inc. today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
› Verified 9 days ago